Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment
Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment
Peripheral blood haematopoietic progenitor cell mobilization has become a standard procedure prior to autologous stem cell transplantation. Biosimilar granulocyte colony-stimulating factors (GCSF) have recently been awarded European Union (EU) licences for stem cell mobilization but data for their use in this context remain limited. The biosimilar GCSF, Ratiograstim(®) (Ratiopharm, Ulm, Germany) was granted an EU licence in September 2008 and incorporated into clinical practice in the Wessex Blood and Marrow Transplantation Programme in December 2008. Data were retrospectively collected for 154 consecutive patients undergoing peripheral blood stem cell harvest between January 2009 and December 2011 using the biosimilar GCSF. 131 consecutive patients from the preceding 3 years, who had received Neupogen(®) , were used as a control. We analysed both parameters relevant to stem cell collection and engraftment data, where patients proceeded to transplantation. We found no statistically significant difference between the two groups when comparing CD34 predictors, total number of CD34(+) stem cells collected, number of days required for collection, or for time to engraftment. This is, to our knowledge, the largest direct comparison of a biosimilar GCSF with originator GCSF for stem cell mobilization. The use of biosimilar GCSF can produce a significant cost saving, allowing investment in other areas of stem cell transplantation.
107-111
Publicover, Amy
0c2c45a4-c13b-4146-9130-f8549beb49ff
Richardson, Deborah S.
7374f16e-f868-426e-9678-555e9666312b
Davies, Andrew
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af
Hill, Kate S.
9f74feac-c36f-46e8-891d-78abdd7c043a
Hurlock, Carol
9687e81e-9b20-4395-bbab-8600088ad87c
Hutchins, David
ed6100da-b0db-444d-9646-7bce3bb46c70
Jenner, Matthew W.
af4d9ce0-1282-4eb3-8440-98b16ee7cc85
Johnson, Peter
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Lamb, Jane
59adf74d-2ed6-4d93-b9d3-8929ffd3d6b2
Launders, Harriet
75b6f6e1-b6fd-4928-837b-27a44c4882ac
McKeag, Nikki
e940ad56-1364-40c4-bb15-f0821965223a
Newman, Joan
67ca8296-d71d-430c-afa9-635fdd1dd4ad
Orchard, Kim H.
794654ab-d6cc-488a-ac11-c9217433c7a2
July 2013
Publicover, Amy
0c2c45a4-c13b-4146-9130-f8549beb49ff
Richardson, Deborah S.
7374f16e-f868-426e-9678-555e9666312b
Davies, Andrew
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af
Hill, Kate S.
9f74feac-c36f-46e8-891d-78abdd7c043a
Hurlock, Carol
9687e81e-9b20-4395-bbab-8600088ad87c
Hutchins, David
ed6100da-b0db-444d-9646-7bce3bb46c70
Jenner, Matthew W.
af4d9ce0-1282-4eb3-8440-98b16ee7cc85
Johnson, Peter
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Lamb, Jane
59adf74d-2ed6-4d93-b9d3-8929ffd3d6b2
Launders, Harriet
75b6f6e1-b6fd-4928-837b-27a44c4882ac
McKeag, Nikki
e940ad56-1364-40c4-bb15-f0821965223a
Newman, Joan
67ca8296-d71d-430c-afa9-635fdd1dd4ad
Orchard, Kim H.
794654ab-d6cc-488a-ac11-c9217433c7a2
Publicover, Amy, Richardson, Deborah S., Davies, Andrew, Hill, Kate S., Hurlock, Carol, Hutchins, David, Jenner, Matthew W., Johnson, Peter, Lamb, Jane, Launders, Harriet, McKeag, Nikki, Newman, Joan and Orchard, Kim H.
(2013)
Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment.
British Journal of Haematology, 162 (1), .
(doi:10.1111/bjh.12345).
(PMID:23614650)
Abstract
Peripheral blood haematopoietic progenitor cell mobilization has become a standard procedure prior to autologous stem cell transplantation. Biosimilar granulocyte colony-stimulating factors (GCSF) have recently been awarded European Union (EU) licences for stem cell mobilization but data for their use in this context remain limited. The biosimilar GCSF, Ratiograstim(®) (Ratiopharm, Ulm, Germany) was granted an EU licence in September 2008 and incorporated into clinical practice in the Wessex Blood and Marrow Transplantation Programme in December 2008. Data were retrospectively collected for 154 consecutive patients undergoing peripheral blood stem cell harvest between January 2009 and December 2011 using the biosimilar GCSF. 131 consecutive patients from the preceding 3 years, who had received Neupogen(®) , were used as a control. We analysed both parameters relevant to stem cell collection and engraftment data, where patients proceeded to transplantation. We found no statistically significant difference between the two groups when comparing CD34 predictors, total number of CD34(+) stem cells collected, number of days required for collection, or for time to engraftment. This is, to our knowledge, the largest direct comparison of a biosimilar GCSF with originator GCSF for stem cell mobilization. The use of biosimilar GCSF can produce a significant cost saving, allowing investment in other areas of stem cell transplantation.
This record has no associated files available for download.
More information
e-pub ahead of print date: 25 April 2013
Published date: July 2013
Organisations:
Cancer Sciences
Identifiers
Local EPrints ID: 353473
URI: http://eprints.soton.ac.uk/id/eprint/353473
ISSN: 0007-1048
PURE UUID: 303888b9-f2be-4231-bca0-9f1667f3db69
Catalogue record
Date deposited: 06 Jun 2013 13:43
Last modified: 15 Mar 2024 03:31
Export record
Altmetrics
Contributors
Author:
Amy Publicover
Author:
Deborah S. Richardson
Author:
Kate S. Hill
Author:
Carol Hurlock
Author:
David Hutchins
Author:
Matthew W. Jenner
Author:
Jane Lamb
Author:
Harriet Launders
Author:
Nikki McKeag
Author:
Joan Newman
Author:
Kim H. Orchard
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics